{"ticker": {"uuid": "7388c806-6af8-483e-bfe9-4089dbc8e7da", "symbol": "BIIB34", "name": "Biogen Inc.", "exchange": "SAO", "country": "BR", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "charts": {"tiers": [{"count": 11, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 3, "label": "Deals and strategy"}, {"count": 3, "label": "Market update"}, {"count": 2, "label": "Earnings"}, {"count": 2, "label": "Analyst action"}, {"count": 1, "label": "Regulatory and legal"}], "sources": [{"label": "finance.yahoo.com", "count": 8}, {"label": "TradingKey", "count": 1}, {"label": "globenewswire.com", "count": 1}, {"label": "Investing.com Canada", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "51/100"}, {"text": "1.89 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "19/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "71/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Market update"}, {"text": "78% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "11"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "8/100"}, {"text": "+0.0% over one week, +9.5% over four weeks, trend active, and near fair-value range.", "tone": "positive", "label": "Trend context", "value": "Trend active"}, {"text": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 3, "event": "general", "label": "Market update", "weight": 1.97}, {"count": 3, "event": "deals", "label": "Deals and strategy", "weight": 1.78}, {"count": 2, "event": "earnings", "label": "Earnings", "weight": 1.1}, {"count": 2, "event": "analyst", "label": "Analyst action", "weight": 1.1}, {"count": 1, "event": "regulatory", "label": "Regulatory and legal", "weight": 0.55}], "pipeline": {"status": "partial", "providers_attempted": 3, "providers_with_results": 1, "raw_articles": 52, "unique_stories": 35, "duplicates_removed": 17, "relevant_stories": 11, "matched_archive_stories": 7, "current_evidence": 3, "direct_evidence": 11, "archive_articles": 2, "durable_story_count": 11, "durable_evidence_used": true, "durable_collected_at": "2026-09-04T13:22:23.795984+00:00"}, "confidence": 71, "primary_event": "general", "primary_label": "Market update", "negative_events": 0, "positive_events": 3}, "updated_at": "2026-09-04T13:26:15.400748+00:00", "total_unique": 11, "total_fetched": 11, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 19, "event_label": "Market update", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "positive", "latest_week": "2026-08-28", "trend_label": "Trend active", "latest_close": 188.289993, "trend_signal": "1", "one_week_move": 0.0, "reaction_tone": "neutral", "fair_value_gap": 14.8, "four_week_move": 9.5, "reaction_label": "Price digesting", "fair_value_tone": "neutral", "market_dynamics": 0.881504, "market_sentence": "+0.0% over one week, +9.5% over four weeks, trend active, and near fair-value range.", "fair_value_label": "Near fair-value range", "twelve_week_move": 16.2, "relative_strength": 14.829546, "has_market_context": true, "expectation_direction": "negative", "expectation_probability": 44.9893, "market_dynamics_buy_signal": false}, "total_relevant": 11, "pipeline_health": {"status": "partial", "providers_attempted": 3, "providers_with_results": 1, "raw_articles": 52, "unique_stories": 35, "duplicates_removed": 17, "relevant_stories": 11, "matched_archive_stories": 7, "current_evidence": 3, "direct_evidence": 11, "archive_articles": 2, "durable_story_count": 11, "durable_evidence_used": true, "durable_collected_at": "2026-09-04T13:26:15.400748+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 51, "total": 11, "neutral": 8, "negative": 0, "positive": 3, "raw_score": 63, "confidence": 19, "dispersion": 8, "story_count": 11, "window_days": 30, "direct_share": 78, "source_count": 1, "score_version": "evidence-v10", "evidence_count": 3, "evidence_status": "provisional", "information_mass": 0.07, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-09-03T23:30:00+00:00", "direct_story_count": 11, "effective_articles": 1.89, "sector_story_count": 0, "direct_source_count": 1, "industry_story_count": 0, "source_concentration": 1.0, "directional_story_count": 3}, "articles": [{"url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html", "tier": "direct", "title": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)", "topics": ["Biotech", "Clinical Trials", "Epilepsy", "Fda Approval", "Neurodevelopment", "Pharma"], "summary": "Biogen Inc. \u20134-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines\u2013 \u2013New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)\u2013 \u2013Improvements in quality of life were demonstrated through 28 months of treatment\u2013 \u2013Zorevunersen generally well tolerated, with some patients treated for more than 5 years\u2013 \u2013Da", "age_days": 0.6, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-03T23:30:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 94.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.062775, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 23:30", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/biogen-biib-stock-could-48-032559262.html", "tier": "direct", "title": "Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data", "topics": ["Balance Sheet", "Biotech", "Earnings", "Free Cash Flow", "Future Cash Flows", "Intrinsic Value"], "summary": "Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track record. Progress with Alzheimer's treatment LEQEMBI and pipeline assets such as the zorevunersen program for Dra", "age_days": 1.4, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/markets/stocks/articles/biogen-biib-stock-could-48-032559262.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-03T03:25:59+00:00", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "freshness_pct": 82.2, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.064391, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 03:25", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/biogen-biib-immunology-bet-meets-074806222.html", "tier": "direct", "title": "Biogen\u2019s (BIIB) Immunology Bet Meets A Pricier Balance Sheet", "topics": ["Biotech", "Earnings", "Immunology", "M A", "Pharma", "Split"], "summary": "On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments capture where Biogen stands right now: a company reshaping itself around newer growth engines while still carrying the weight of its aging multiple sclerosis business.Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet A Pipeline Getting Real ", "age_days": 2.2, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biogen-biib-immunology-bet-meets-074806222.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-02T07:48:06+00:00", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "freshness_pct": 80.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.047471, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "02 Sep 2026 07:48", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/why-biogen-biib-6-5-153024739.html", "tier": "direct", "title": "Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?", "topics": ["Acquisition", "Biotech", "Consensus Estimate", "Earnings", "Earnings Per Share", "Earnings Release"], "summary": "It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 6.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Biogen Inc. before we dive into how investors and analysts have reacted as of late. Q2 Earnings & Sales Beat Biogen reported second-quarter 2026 adjusted earnings per share (EPS) of $3.60, which signi", "age_days": 6.9, "is_stale": false, "sentiment": "positive", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/why-biogen-biib-6-5-153024739.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-28T15:30:24+00:00", "tone_signals": ["Beat expectations"], "company_focus": 0.78, "freshness_pct": 50.4, "sentiment_pct": 61, "evidence_basis": "archived_article", "evidence_share": 69.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.04854, "influence_label": "Medium", "event_confidence": 77, "company_focus_pct": 78, "evidence_strength": 45, "published_display": "28 Aug 2026 15:30", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "69.1"}, {"url": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-biogen-110300455.html", "tier": "direct", "title": "Veeva Vault CRM Selected by Biogen", "topics": ["Biotech", "Crm", "Pharma"], "summary": "Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Biogen \"We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives,\" said Tom Schwenger, president and CCO at Veeva. \"Bringing complex treatments to market requires a highly adaptive commercial strategy, and we are committed to providing the advanced capabilities ", "age_days": 10.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-biogen-110300455.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-25T11:03:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 3.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.001135, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "25 Aug 2026 11:03", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/biogen-biib-undervalued-raised-eps-170939503.html", "tier": "direct", "title": "Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?", "topics": ["Alzheimers", "Balance Sheet", "Biotech", "Guidance", "Neurology", "Price Target"], "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 y", "age_days": 13.8, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biogen-biib-undervalued-raised-eps-170939503.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-21T17:09:39+00:00", "tone_signals": ["Guidance raised", "Positive valuation view"], "company_focus": 0.78, "freshness_pct": 4.1, "sentiment_pct": 84, "evidence_basis": "archived_article", "evidence_share": 11.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.008048, "influence_label": "High", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 59, "published_display": "21 Aug 2026 17:09", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "11.5"}, {"url": "https://finance.yahoo.com/healthcare/articles/biogen-biib-higher-earnings-guidance-131337483.html", "tier": "direct", "title": "What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders", "topics": ["Biotech", "Clinical Trials", "Earnings", "Guidance"], "summary": "In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company's long-term profile. Next, we'll examine how Biogen's higher earnings guidance and advancing late-stage pipeline may influence its existing investment narrative. The best AI stocks today may lie beyo", "age_days": 14.0, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biogen-biib-higher-earnings-guidance-131337483.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-21T13:13:37+00:00", "tone_signals": ["Guidance raised"], "company_focus": 0.78, "freshness_pct": 14.3, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 19.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.013681, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 35, "published_display": "21 Aug 2026 13:13", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "19.5"}, {"url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "tier": "direct", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "topics": ["Balance Sheet", "Clinical Trials", "Earnings", "Earnings Growth", "Pharma", "Price Target"], "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "age_days": 22.0, "is_stale": false, "sentiment": "neutral", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-13T13:52:01+00:00", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "freshness_pct": 0.6, "sentiment_pct": 54, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00038, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "13 Aug 2026 13:52", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE85d1hSWDE0RUViQmVyM2V4SVFPOE5ycG1DeEFMNklIOU5VZHE5VWdaRjBxRXJIT2d1M0xQeWVWQnFTWE8zR3dkelpPWm50c2dUNVBpYXdQODJHaXRFS182MWl1WG1OWkVMN2c?oc=5", "tier": "direct", "title": "Proje\u00e7\u00f5es de Resultados: Biogen Inc (BIIB) \u2014 LPA e Crescimento de Receita", "topics": [], "summary": "", "age_days": 28.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiakFVX3lxTE85d1hSWDE0RUViQmVyM2V4SVFPOE5ycG1DeEFMNklIOU5VZHE5VWdaRjBxRXJIT2d1M0xQeWVWQnFTWE8zR3dkelpPWm50c2dUNVBpYXdQODJHaXRFS182MWl1WG1OWkVMN2c?oc=5", "source_name": "TradingKey", "published_at": "2026-08-07T09:18:27+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 09:18", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.globenewswire.com/news-release/2026/08/06/3340877/0/en/Biogen-Completes-Acquisition-of-RayThera-Inc.html", "tier": "direct", "title": "Biogen Completes Acquisition of RayThera Inc.", "topics": ["Biotech", "Health", "Immunology", "M A", "Mergers And Acquisitions", "Press Releases"], "summary": "CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen\u2019s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026. \u201cWe are excited about the potential of these immunology assets as we continue to strengthen and dive", "age_days": 28.6, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/08/06/3340877/0/en/Biogen-Completes-Acquisition-of-RayThera-Inc.html", "source_name": "globenewswire.com", "published_at": "2026-08-06T22:15:00+00:00", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "freshness_pct": 5.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.004958, "influence_label": "None", "event_confidence": 96, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "06 Aug 2026 22:15", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "", "tier": "direct", "title": "Form 144 BIOGEN INC. For: 3 August By Investing.com", "topics": [], "summary": "", "age_days": 29.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.google.com/search?tbm=nws&q=%22Form+144+BIOGEN+INC.+For%3A+3+August+By+Investing.com%22+%22Investing.com+Canada%22", "source_name": "Investing.com Canada", "published_at": "2026-08-06T10:20:33.819803+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 10:20", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": true, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html", "tier": "direct", "title": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)", "topics": ["Biotech", "Clinical Trials", "Epilepsy", "Fda Approval", "Neurodevelopment", "Pharma"], "summary": "Biogen Inc. \u20134-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines\u2013 \u2013New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)\u2013 \u2013Improvements in quality of life were demonstrated through 28 months of treatment\u2013 \u2013Zorevunersen generally well tolerated, with some patients treated for more than 5 years\u2013 \u2013Da", "age_days": 0.6, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "6a6517bb6aa6b40ec9fb2b6be6c94a54ed3aeb09b0076bda569e52e573714db7", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-03T23:30:00+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Biogen Inc.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 94.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 3, "durable_archive": false, "evidence_weight": 0.062775, "influence_label": "None", "provider_symbol": "BIIB.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.4, "provider_symbols": ["BIIB.MX", "BIIB.US", "BIIB34.ARCHIVE", "IDP.DU", "IDP.HM", "IDP.MU", "STOK.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 23:30", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.168}, {"url": "https://finance.yahoo.com/markets/stocks/articles/biogen-biib-stock-could-48-032559262.html", "tier": "direct", "title": "Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data", "topics": ["Balance Sheet", "Biotech", "Earnings", "Free Cash Flow", "Future Cash Flows", "Intrinsic Value"], "summary": "Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track record. Progress with Alzheimer's treatment LEQEMBI and pipeline assets such as the zorevunersen program for Dra", "age_days": 1.4, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "6718bcabc6f3feb4835d35dd7b8208f5dfbf4d52733bf32eef14cd38cd3ad15c", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/markets/stocks/articles/biogen-biib-stock-could-48-032559262.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-03T03:25:59+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track record.", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 82.2, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.064391, "influence_label": "None", "provider_symbol": "BIIB.US", "relevance_score": 0.795492, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.471, "provider_symbols": ["BIIB.MX", "BIIB.US", "BIIB34.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 03:25", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.1179}, {"url": "https://finance.yahoo.com/healthcare/articles/biogen-biib-immunology-bet-meets-074806222.html", "tier": "direct", "title": "Biogen\u2019s (BIIB) Immunology Bet Meets A Pricier Balance Sheet", "topics": ["Biotech", "Earnings", "Immunology", "M A", "Pharma", "Split"], "summary": "On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments capture where Biogen stands right now: a company reshaping itself around newer growth engines while still carrying the weight of its aging multiple sclerosis business.Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet A Pipeline Getting Real ", "age_days": 2.2, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "a260b4d8e6e815bee9d22689dc61a3fd23399c35f705edf161c827818e9d670a", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biogen-biib-immunology-bet-meets-074806222.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-02T07:48:06+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Biogen\u2019s (BIIB) Immunology Bet Meets A Pricier Balance Sheet On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. Together, the two moments capture where Biogen stands right now: a company reshaping itself around newer growth engines while still carrying the weight of its aging multiple sclerosis business.Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet A Pipeline Getting Real", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 80.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.047471, "influence_label": "None", "provider_symbol": "BIIB.US", "relevance_score": 0.795492, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.45, "provider_symbols": ["BIIB.US", "BIIB34.ARCHIVE", "PFE.BA"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "02 Sep 2026 07:48", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.134}, {"url": "https://finance.yahoo.com/healthcare/articles/why-biogen-biib-6-5-153024739.html", "tier": "direct", "title": "Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?", "topics": ["Acquisition", "Biotech", "Consensus Estimate", "Earnings", "Earnings Per Share", "Earnings Release"], "summary": "It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 6.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Biogen Inc. before we dive into how investors and analysts have reacted as of late. Q2 Earnings & Sales Beat Biogen reported second-quarter 2026 adjusted earnings per share (EPS) of $3.60, which signi", "age_days": 6.9, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "positive", "story_key": "32e995320c3f1524a275a2306deeeffc97e47df4d8105dadd6d8a139ba147176", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/why-biogen-biib-6-5-153024739.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-28T15:30:24+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? It has been about a month since the last earnings report for Biogen Inc. Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Biogen Inc. Q2 Earnings & Sales Beat Biogen reported second-quarter 2026 adjusted earnings per share (EPS) of $3.60, which signi", "tone_signals": ["Beat expectations"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 50.4, "sentiment_pct": 61, "evidence_basis": "archived_article", "evidence_share": 69.1, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.04854, "influence_label": "Medium", "provider_symbol": "BIIB.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.561, "provider_symbols": ["BIIB.US", "BIIB34.ARCHIVE", "GSPC.INDX", "IDP.MU"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 45, "published_display": "28 Aug 2026 15:30", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "69.1", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.1}, {"url": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-biogen-110300455.html", "tier": "direct", "title": "Veeva Vault CRM Selected by Biogen", "topics": ["Biotech", "Crm", "Pharma"], "summary": "Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Biogen \"We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives,\" said Tom Schwenger, president and CCO at Veeva. \"Bringing complex treatments to market requires a highly adaptive commercial strategy, and we are committed to providing the advanced capabilities ", "age_days": 10.1, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "6378c91a140da0b237a4ed9cbf6e92d5014e0b14e76903b6fc70c7a21a4b11fa", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-biogen-110300455.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-25T11:03:00+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Veeva Vault CRM Selected by Biogen 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Biogen \"We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives,\" said Tom Schwenger, president and CCO at Veeva.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.001135, "influence_label": "None", "provider_symbol": "BIIB.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BIIB.US", "BIIB34.ARCHIVE", "CRM.US", "VEEV.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "25 Aug 2026 11:03", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.148}, {"url": "https://finance.yahoo.com/healthcare/articles/biogen-biib-undervalued-raised-eps-170939503.html", "tier": "direct", "title": "Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?", "topics": ["Alzheimers", "Balance Sheet", "Biotech", "Guidance", "Neurology", "Price Target"], "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 y", "age_days": 13.8, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "positive", "story_key": "dc17dc4180494275c3a7c73794d88b64b362a7ebd1ef8ea69209a0b4770414f4", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biogen-biib-undervalued-raised-eps-170939503.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-21T17:09:39+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts? Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 y", "tone_signals": ["Guidance raised", "Positive valuation view"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.1, "sentiment_pct": 84, "evidence_basis": "archived_article", "evidence_share": 11.5, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.008048, "influence_label": "High", "provider_symbol": "BIIB.US", "relevance_score": 0.795492, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.83, "provider_symbols": ["BIIB.US", "BIIB34.ARCHIVE", "BIIB34.SA"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 59, "published_display": "21 Aug 2026 17:09", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "11.5", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.16}, {"url": "https://finance.yahoo.com/healthcare/articles/biogen-biib-higher-earnings-guidance-131337483.html", "tier": "direct", "title": "What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders", "topics": ["Biotech", "Clinical Trials", "Earnings", "Guidance"], "summary": "In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company's long-term profile. Next, we'll examine how Biogen's higher earnings guidance and advancing late-stage pipeline may influence its existing investment narrative. The best AI stocks today may lie beyo", "age_days": 14.0, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "positive", "story_key": "03a1db1a86c6e60f3970a855651caae160af3992ffdc77dbd661cf94ba157009", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biogen-biib-higher-earnings-guidance-131337483.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-21T13:13:37+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. Next, we'll examine how Biogen's higher earnings guidance and advancing late-stage pipeline may influence its existing investment narrative.", "tone_signals": ["Guidance raised"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 14.3, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 19.5, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.013681, "influence_label": "Low", "provider_symbol": "BIIB.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.541, "provider_symbols": ["BIIB.US", "BIIB34.ARCHIVE", "MSFT.US", "NVDA.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 35, "published_display": "21 Aug 2026 13:13", "direction_included": true, "sentiment_conflict": 0.194, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "19.5", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.179}, {"url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "tier": "direct", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "topics": ["Balance Sheet", "Clinical Trials", "Earnings", "Earnings Growth", "Pharma", "Price Target"], "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "age_days": 22.0, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-13T13:52:01+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations.", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.6, "sentiment_pct": 54, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.00038, "influence_label": "None", "provider_symbol": "BIIB.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.47, "provider_symbols": ["ABBV.US", "BIIB.US", "BIIB34.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "13 Aug 2026 13:52", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.164}, {"url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE85d1hSWDE0RUViQmVyM2V4SVFPOE5ycG1DeEFMNklIOU5VZHE5VWdaRjBxRXJIT2d1M0xQeWVWQnFTWE8zR3dkelpPWm50c2dUNVBpYXdQODJHaXRFS182MWl1WG1OWkVMN2c?oc=5", "tier": "direct", "title": "Proje\u00e7\u00f5es de Resultados: Biogen Inc (BIIB) \u2014 LPA e Crescimento de Receita", "topics": [], "summary": "", "age_days": 28.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "53126a804ca351bbe5d5feac0140fabc28f7b7bcb39773b0265390cb312912c6", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiakFVX3lxTE85d1hSWDE0RUViQmVyM2V4SVFPOE5ycG1DeEFMNklIOU5VZHE5VWdaRjBxRXJIT2d1M0xQeWVWQnFTWE8zR3dkelpPWm50c2dUNVBpYXdQODJHaXRFS182MWl1WG1OWkVMN2c?oc=5", "source_name": "TradingKey", "published_at": "2026-08-07T09:18:27+00:00", "source_names": ["TradingKey"], "target_scope": "Proje\u00e7\u00f5es de Resultados: Biogen Inc (BIIB) \u2014 LPA e Crescimento de Receita", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BIIB34.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 09:18", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB34.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.globenewswire.com/news-release/2026/08/06/3340877/0/en/Biogen-Completes-Acquisition-of-RayThera-Inc.html", "tier": "direct", "title": "Biogen Completes Acquisition of RayThera Inc.", "topics": ["Biotech", "Health", "Immunology", "M A", "Mergers And Acquisitions", "Press Releases"], "summary": "CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen\u2019s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026. \u201cWe are excited about the potential of these immunology assets as we continue to strengthen and dive", "age_days": 28.6, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "ab46db3b3e0634b469ec629e914e663c9a7f5701b4b492f1d204588d265fc838", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/08/06/3340877/0/en/Biogen-Completes-Acquisition-of-RayThera-Inc.html", "source_name": "globenewswire.com", "published_at": "2026-08-06T22:15:00+00:00", "source_names": ["globenewswire.com"], "target_scope": "Biogen Completes Acquisition of RayThera Inc. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. The acquisition strengthens Biogen\u2019s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications.", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.004958, "influence_label": "None", "provider_symbol": "BIIB.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 96, "model_confidence": 0.45, "provider_symbols": ["BIIB.US", "BIIB34.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "06 Aug 2026 22:15", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BIIB.US", "provider_directional_mass": 0.155}, {"url": "", "tier": "direct", "title": "Form 144 BIOGEN INC. For: 3 August By Investing.com", "topics": [], "summary": "", "age_days": 29.1, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "b997298f356e5d95c0856aa2d3203cef6d16f3a356d306add2cdc5250b51ac02", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.google.com/search?tbm=nws&q=%22Form+144+BIOGEN+INC.+For%3A+3+August+By+Investing.com%22+%22Investing.com+Canada%22", "source_name": "Investing.com Canada", "published_at": "2026-08-06T10:20:33.819803+00:00", "source_names": ["Investing.com Canada"], "target_scope": "Form 144 BIOGEN INC.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "snapshot", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BIIB34.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 10:20", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": true, "evidence_share_display": "0", "target_provider_symbol": "BIIB34.ARCHIVE", "provider_directional_mass": null}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "11 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 51, "display": "51", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 19, "display": "19", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 78, "display": "78%", "tone": "positive", "note": "11 company stories"}, {"label": "Story agreement", "value": 92, "display": "92", "tone": "positive", "note": "8/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 1, "note": "0.07 after freshness weighting"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Company relevance", "value": 78, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 61, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 92, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 0, "note": "less reliance on one publisher"}], "freshness": 61, "source_independence": 0, "timeline": [{"date": "2026-08-06", "label": "06 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 1, "score": 54, "tone": "neutral", "x": 263.1, "y": 127.7, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-15", "label": "15 Aug", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-16", "label": "16 Aug", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-17", "label": "17 Aug", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-18", "label": "18 Aug", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-19", "label": "19 Aug", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-20", "label": "20 Aug", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-21", "label": "21 Aug", "count": 2, "score": 67, "tone": "positive", "x": 515.8, "y": 104.1, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-22", "label": "22 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-23", "label": "23 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-24", "label": "24 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-25", "label": "25 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-26", "label": "26 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-27", "label": "27 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-28", "label": "28 Aug", "count": 1, "score": 61, "tone": "positive", "x": 736.9, "y": 115.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-01", "label": "01 Sep", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-02", "label": "02 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-09-03", "label": "03 Sep", "count": 2, "score": 53, "tone": "neutral", "x": 926.4, "y": 129.5, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-09-04", "label": "04 Sep", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 73.6,135.0 263.1,127.7 515.8,104.1 642.1,135.0 736.9,115.0 894.8,135.0 926.4,129.5", "timeline_has_signal": true, "timeline_start": "06 Aug", "timeline_mid": "21 Aug", "timeline_end": "04 Sep", "momentum": {"label": "Establishing", "tone": "neutral", "recent_score": 52, "prior_score": null, "delta": null, "recent_count": 3, "prior_count": 0, "volume_delta": 3, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "New stories need a baseline", "tone": "neutral", "latest_score": 50, "baseline_score": 55, "delta": null, "latest_count": 1, "baseline_count": 3, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 1, "share": 9}, {"label": "1 to 3 days", "count": 2, "share": 18}, {"label": "4 to 7 days", "count": 1, "share": 9}, {"label": "8 to 14 days", "count": 2, "share": 18}, {"label": "15 to 21 days", "count": 1, "share": 9}, {"label": "22 to 30 days", "count": 4, "share": 36}], "source_profile": [{"label": "finance.yahoo.com", "count": 8, "share": 73, "score": 55, "tone": "neutral"}, {"label": "TradingKey", "count": 1, "share": 9, "score": 50, "tone": "neutral"}, {"label": "globenewswire.com", "count": 1, "share": 9, "score": 50, "tone": "neutral"}, {"label": "Investing.com Canada", "count": 1, "share": 9, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Deals and strategy", "count": 3, "share": 27, "score": 55, "tone": "neutral"}, {"label": "Market update", "count": 3, "share": 27, "score": 50, "tone": "neutral"}, {"label": "Analyst action", "count": 2, "share": 18, "score": 83, "tone": "positive"}, {"label": "Earnings", "count": 2, "share": 18, "score": 55, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 1, "share": 9, "score": 50, "tone": "neutral"}], "topics": [{"label": "Biotech", "count": 8, "share": 73}, {"label": "Earnings", "count": 5, "share": 45}, {"label": "Pharma", "count": 4, "share": 36}, {"label": "Clinical Trials", "count": 3, "share": 27}, {"label": "Balance Sheet", "count": 3, "share": 27}, {"label": "Price Target", "count": 2, "share": 18}, {"label": "M A", "count": 2, "share": 18}, {"label": "Immunology", "count": 2, "share": 18}, {"label": "Guidance", "count": 2, "share": 18}, {"label": "Split", "count": 1, "share": 9}], "supporting": [{"label": "Direct evidence", "text": "11 current stories are mapped specifically to BIIB34."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}, {"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.070."}, {"label": "Confidence", "text": "Confidence is 19/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html", "tier": "direct", "title": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)", "topics": ["Biotech", "Clinical Trials", "Epilepsy", "Fda Approval", "Neurodevelopment", "Pharma"], "summary": "Biogen Inc. \u20134-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines\u2013 \u2013New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)\u2013 \u2013Improvements in quality of life were demonstrated through 28 months of treatment\u2013 \u2013Zorevunersen generally well tolerated, with some patients treated for more than 5 years\u2013 \u2013Da", "age_days": 0.6, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html", "source_name": "finance.yahoo.com", "published_at": "2026-09-03T23:30:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 94.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.062775, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 23:30", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 11, "updated_at": "2026-09-04T13:26:15.400748+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 144.7, "label": "06 Mar 2026", "close": 164.729996, "index": 100.0}, {"x": 78.4, "y": 152.7, "label": "13 Mar 2026", "close": 162.589996, "index": 98.7}, {"x": 114.9, "y": 152.7, "label": "20 Mar 2026", "close": 162.589996, "index": 98.7}, {"x": 151.3, "y": 152.7, "label": "27 Mar 2026", "close": 162.589996, "index": 98.7}, {"x": 187.7, "y": 152.7, "label": "03 Apr 2026", "close": 162.589996, "index": 98.7}, {"x": 224.2, "y": 201.4, "label": "10 Apr 2026", "close": 149.699997, "index": 90.9}, {"x": 260.6, "y": 204.2, "label": "17 Apr 2026", "close": 148.949997, "index": 90.4}, {"x": 297.0, "y": 188.2, "label": "24 Apr 2026", "close": 153.199997, "index": 93.0}, {"x": 333.5, "y": 163.3, "label": "01 May 2026", "close": 159.800003, "index": 97.0}, {"x": 369.9, "y": 169.8, "label": "08 May 2026", "close": 158.080002, "index": 96.0}, {"x": 406.3, "y": 154.1, "label": "15 May 2026", "close": 162.240005, "index": 98.5}, {"x": 442.8, "y": 172.8, "label": "22 May 2026", "close": 157.279999, "index": 95.5}, {"x": 479.2, "y": 154.7, "label": "29 May 2026", "close": 162.080002, "index": 98.4}, {"x": 515.6, "y": 154.7, "label": "05 Jun 2026", "close": 162.080002, "index": 98.4}, {"x": 552.0, "y": 154.7, "label": "12 Jun 2026", "close": 162.080002, "index": 98.4}, {"x": 588.5, "y": 154.7, "label": "19 Jun 2026", "close": 162.080002, "index": 98.4}, {"x": 624.9, "y": 154.7, "label": "26 Jun 2026", "close": 162.080002, "index": 98.4}, {"x": 661.3, "y": 71.6, "label": "03 Jul 2026", "close": 184.100006, "index": 111.8}, {"x": 697.8, "y": 123.5, "label": "10 Jul 2026", "close": 170.339996, "index": 103.4}, {"x": 734.2, "y": 123.5, "label": "17 Jul 2026", "close": 170.339996, "index": 103.4}, {"x": 770.6, "y": 123.5, "label": "24 Jul 2026", "close": 170.339996, "index": 103.4}, {"x": 807.1, "y": 117.3, "label": "31 Jul 2026", "close": 172.0, "index": 104.4}, {"x": 843.5, "y": 117.3, "label": "07 Aug 2026", "close": 172.0, "index": 104.4}, {"x": 879.9, "y": 117.3, "label": "14 Aug 2026", "close": 172.0, "index": 104.4}, {"x": 916.4, "y": 55.8, "label": "21 Aug 2026", "close": 188.289993, "index": 114.3}, {"x": 952.8, "y": 55.8, "label": "28 Aug 2026", "close": 188.289993, "index": 114.3}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "tone": "neutral", "close": 162.080002, "label": "26 Jun 2026", "score": 50, "stories": 2, "raw_score": 57, "confidence": 26, "price_change": 0.0, "x": 630.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "tone": "neutral", "close": 184.100006, "label": "03 Jul 2026", "score": 51, "stories": 4, "raw_score": 66, "confidence": 23, "price_change": 13.6, "x": 666.5, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "tone": "neutral", "close": 170.339996, "label": "10 Jul 2026", "score": 50, "stories": 5, "raw_score": 40, "confidence": 18, "price_change": -7.5, "x": 703.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 170.339996, "label": "17 Jul 2026", "score": 50, "stories": 7, "raw_score": 40, "confidence": 15, "price_change": 0.0, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 170.339996, "label": "24 Jul 2026", "score": 47, "stories": 9, "raw_score": 30, "confidence": 27, "price_change": 0.0, "x": 775.8, "y": 135.5, "show_label": true, "label_y": 125.5}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "positive", "close": 172.0, "label": "31 Jul 2026", "score": 60, "stories": 19, "raw_score": 68, "confidence": 43, "price_change": 1.0, "x": 812.3, "y": 111.6, "show_label": false, "label_y": 101.6}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "positive", "close": 172.0, "label": "07 Aug 2026", "score": 58, "stories": 23, "raw_score": 70, "confidence": 34, "price_change": 0.0, "x": 848.7, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 172.0, "label": "14 Aug 2026", "score": 56, "stories": 26, "raw_score": 68, "confidence": 30, "price_change": 0.0, "x": 885.1, "y": 119.0, "show_label": false, "label_y": 109.0}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "positive", "close": 188.289993, "label": "21 Aug 2026", "score": 58, "stories": 25, "raw_score": 73, "confidence": 32, "price_change": 9.5, "x": 921.6, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 188.289993, "label": "28 Aug 2026", "score": 54, "stories": 17, "raw_score": 68, "confidence": 26, "price_change": 0.0, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}], "price_path": "42.0,144.7 78.4,152.7 114.9,152.7 151.3,152.7 187.7,152.7 224.2,201.4 260.6,204.2 297.0,188.2 333.5,163.3 369.9,169.8 406.3,154.1 442.8,172.8 479.2,154.7 515.6,154.7 552.0,154.7 588.5,154.7 624.9,154.7 661.3,71.6 697.8,123.5 734.2,123.5 770.6,123.5 807.1,117.3 843.5,117.3 879.9,117.3 916.4,55.8 952.8,55.8", "sentiment_path": "630.1,130.0 666.5,128.2 703.0,130.0 739.4,130.0 775.8,135.5 812.3,111.6 848.7,115.3 885.1,119.0 921.6,115.3 958.0,122.6", "score_version": "evidence-v10", "price_change": 14.3, "sentiment_change": 4, "recent_pairs": [{"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 188.289993, "label": "28 Aug 2026", "score": 54, "stories": 17, "raw_score": 68, "confidence": 26, "price_change": 0.0, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "positive", "close": 188.289993, "label": "21 Aug 2026", "score": 58, "stories": 25, "raw_score": 73, "confidence": 32, "price_change": 9.5, "x": 921.6, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 172.0, "label": "14 Aug 2026", "score": 56, "stories": 26, "raw_score": 68, "confidence": 30, "price_change": 0.0, "x": 885.1, "y": 119.0, "show_label": false, "label_y": 109.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "positive", "close": 172.0, "label": "07 Aug 2026", "score": 58, "stories": 23, "raw_score": 70, "confidence": 34, "price_change": 0.0, "x": 848.7, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "positive", "close": 172.0, "label": "31 Jul 2026", "score": 60, "stories": 19, "raw_score": 68, "confidence": 43, "price_change": 1.0, "x": 812.3, "y": 111.6, "show_label": false, "label_y": 101.6}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 170.339996, "label": "24 Jul 2026", "score": 47, "stories": 9, "raw_score": 30, "confidence": 27, "price_change": 0.0, "x": 775.8, "y": 135.5, "show_label": true, "label_y": 125.5}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 170.339996, "label": "17 Jul 2026", "score": 50, "stories": 7, "raw_score": 40, "confidence": 15, "price_change": 0.0, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "tone": "neutral", "close": 170.339996, "label": "10 Jul 2026", "score": 50, "stories": 5, "raw_score": 40, "confidence": 18, "price_change": -7.5, "x": 703.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 188.289993, "price_observations": 26, "sentiment_observations": 10, "sentiment_start_label": "26 Jun 2026", "sentiment_end_label": "28 Aug 2026", "sentiment_history_limited": false, "price_axis_high": 117.2, "price_axis_mid": 102.4, "price_axis_low": 87.6, "start_label": "06 Mar", "mid_label": "02 Jun", "end_label": "28 Aug", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start"}, {"tone": "neutral", "delta": 0, "label": "26 Jun 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 26, "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 26, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "02 Jul 23:59", "score": 51, "height": 4, "articles": 3, "confidence": 27, "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+1"}, {"tone": "neutral", "delta": 1, "label": "03 Jul 23:59", "score": 51, "height": 4, "articles": 4, "confidence": 23, "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0"}, {"tone": "neutral", "delta": -1, "label": "07 Jul 23:59", "score": 49, "height": 4, "articles": 5, "confidence": 25, "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "-2"}, {"tone": "neutral", "delta": 0, "label": "13 Jul 23:59", "score": 50, "height": 4, "articles": 6, "confidence": 16, "short_label": "13 Jul", "collected_at": "2026-07-13T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "+1"}, {"tone": "neutral", "delta": 0, "label": "17 Jul 23:59", "score": 50, "height": 4, "articles": 7, "confidence": 15, "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": -4, "label": "22 Jul 23:59", "score": 46, "height": 8, "articles": 9, "confidence": 32, "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score_change": -4, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 17, "score_change_display": "-4"}, {"tone": "neutral", "delta": -2, "label": "28 Jul 23:59", "score": 48, "height": 4, "articles": 9, "confidence": 21, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -11, "score_change_display": "+2"}, {"tone": "positive", "delta": 13, "label": "29 Jul 23:59", "score": 63, "height": 26, "articles": 17, "confidence": 46, "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score_change": 15, "reconstructed": true, "score_version": "evidence-v10", "article_change": 8, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 25, "score_change_display": "+15"}, {"tone": "positive", "delta": 13, "label": "30 Jul 23:59", "score": 63, "height": 26, "articles": 18, "confidence": 44, "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "positive", "delta": 10, "label": "31 Jul 23:59", "score": 60, "height": 20, "articles": 19, "confidence": 43, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -1, "score_change_display": "-3"}, {"tone": "positive", "delta": 10, "label": "01 Aug 23:59", "score": 60, "height": 20, "articles": 20, "confidence": 41, "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 7, "label": "05 Aug 23:59", "score": 57, "height": 14, "articles": 20, "confidence": 31, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -10, "score_change_display": "-3"}, {"tone": "neutral", "delta": 7, "label": "06 Aug 23:59", "score": 57, "height": 14, "articles": 21, "confidence": 29, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "positive", "delta": 8, "label": "07 Aug 23:59", "score": 58, "height": 16, "articles": 23, "confidence": 34, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+1"}, {"tone": "neutral", "delta": 6, "label": "11 Aug 23:59", "score": 56, "height": 12, "articles": 25, "confidence": 27, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -7, "score_change_display": "-2"}, {"tone": "neutral", "delta": 5, "label": "13 Aug 23:59", "score": 55, "height": 10, "articles": 25, "confidence": 25, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 6, "label": "14 Aug 23:59", "score": 56, "height": 12, "articles": 26, "confidence": 30, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+1"}, {"tone": "positive", "delta": 8, "label": "21 Aug 23:59", "score": 58, "height": 16, "articles": 25, "confidence": 32, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "+2"}, {"tone": "neutral", "delta": 5, "label": "25 Aug 23:59", "score": 55, "height": 10, "articles": 26, "confidence": 25, "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -7, "score_change_display": "-3"}, {"tone": "neutral", "delta": 4, "label": "28 Aug 23:59", "score": 54, "height": 8, "articles": 17, "confidence": 26, "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -9, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "02 Sep 23:59", "score": 52, "height": 4, "articles": 14, "confidence": 20, "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": -3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-2"}, {"tone": "neutral", "delta": 2, "label": "03 Sep 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 19, "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "04 Sep 13:22", "score": 52, "height": 4, "articles": 15, "confidence": 19, "short_label": "04 Sep", "collected_at": "2026-09-04T13:22:23.652045+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 25, "span_label": "71 days", "first_score": 50, "latest_score": 52, "net_change": 2, "net_change_display": "+2", "direction": "Broadly stable", "high_score": 63, "low_score": 46, "latest_confidence": 19, "confidence_change": 19, "latest_articles": 15, "article_change": 14, "latest_label": "04 Sep 13:22", "latest_evidence_label": "Provisional", "chart_rows": [{"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start", "x": 42.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "26 Jun 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 26, "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 26, "score_change_display": "+0", "x": 80.2, "y": 135.0}, {"tone": "neutral", "delta": 1, "label": "02 Jul 23:59", "score": 51, "height": 4, "articles": 3, "confidence": 27, "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+1", "x": 118.3, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "03 Jul 23:59", "score": 51, "height": 4, "articles": 4, "confidence": 23, "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0", "x": 156.5, "y": 133.2}, {"tone": "neutral", "delta": -1, "label": "07 Jul 23:59", "score": 49, "height": 4, "articles": 5, "confidence": 25, "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "-2", "x": 194.7, "y": 136.8}, {"tone": "neutral", "delta": 0, "label": "13 Jul 23:59", "score": 50, "height": 4, "articles": 6, "confidence": 16, "short_label": "13 Jul", "collected_at": "2026-07-13T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "+1", "x": 232.8, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "17 Jul 23:59", "score": 50, "height": 4, "articles": 7, "confidence": 15, "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 271.0, "y": 135.0}, {"tone": "neutral", "delta": -4, "label": "22 Jul 23:59", "score": 46, "height": 8, "articles": 9, "confidence": 32, "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score_change": -4, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 17, "score_change_display": "-4", "x": 309.2, "y": 142.3}, {"tone": "neutral", "delta": -2, "label": "28 Jul 23:59", "score": 48, "height": 4, "articles": 9, "confidence": 21, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -11, "score_change_display": "+2", "x": 347.3, "y": 138.6}, {"tone": "positive", "delta": 13, "label": "29 Jul 23:59", "score": 63, "height": 26, "articles": 17, "confidence": 46, "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score_change": 15, "reconstructed": true, "score_version": "evidence-v10", "article_change": 8, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 25, "score_change_display": "+15", "x": 385.5, "y": 111.3}, {"tone": "positive", "delta": 13, "label": "30 Jul 23:59", "score": 63, "height": 26, "articles": 18, "confidence": 44, "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0", "x": 423.7, "y": 111.3}, {"tone": "positive", "delta": 10, "label": "31 Jul 23:59", "score": 60, "height": 20, "articles": 19, "confidence": 43, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -1, "score_change_display": "-3", "x": 461.8, "y": 116.8}, {"tone": "positive", "delta": 10, "label": "01 Aug 23:59", "score": 60, "height": 20, "articles": 20, "confidence": 41, "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0", "x": 500.0, "y": 116.8}, {"tone": "neutral", "delta": 7, "label": "05 Aug 23:59", "score": 57, "height": 14, "articles": 20, "confidence": 31, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -10, "score_change_display": "-3", "x": 538.2, "y": 122.3}, {"tone": "neutral", "delta": 7, "label": "06 Aug 23:59", "score": 57, "height": 14, "articles": 21, "confidence": 29, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 576.3, "y": 122.3}, {"tone": "positive", "delta": 8, "label": "07 Aug 23:59", "score": 58, "height": 16, "articles": 23, "confidence": 34, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+1", "x": 614.5, "y": 120.4}, {"tone": "neutral", "delta": 6, "label": "11 Aug 23:59", "score": 56, "height": 12, "articles": 25, "confidence": 27, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -7, "score_change_display": "-2", "x": 652.7, "y": 124.1}, {"tone": "neutral", "delta": 5, "label": "13 Aug 23:59", "score": 55, "height": 10, "articles": 25, "confidence": 25, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1", "x": 690.8, "y": 125.9}, {"tone": "neutral", "delta": 6, "label": "14 Aug 23:59", "score": 56, "height": 12, "articles": 26, "confidence": 30, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+1", "x": 729.0, "y": 124.1}, {"tone": "positive", "delta": 8, "label": "21 Aug 23:59", "score": 58, "height": 16, "articles": 25, "confidence": 32, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "+2", "x": 767.2, "y": 120.4}, {"tone": "neutral", "delta": 5, "label": "25 Aug 23:59", "score": 55, "height": 10, "articles": 26, "confidence": 25, "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -7, "score_change_display": "-3", "x": 805.3, "y": 125.9}, {"tone": "neutral", "delta": 4, "label": "28 Aug 23:59", "score": 54, "height": 8, "articles": 17, "confidence": 26, "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -9, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "-1", "x": 843.5, "y": 127.7}, {"tone": "neutral", "delta": 2, "label": "02 Sep 23:59", "score": 52, "height": 4, "articles": 14, "confidence": 20, "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": -3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-2", "x": 881.7, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "03 Sep 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 19, "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 919.8, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "04 Sep 13:22", "score": 52, "height": 4, "articles": 15, "confidence": 19, "short_label": "04 Sep", "collected_at": "2026-09-04T13:22:23.652045+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 958.0, "y": 131.4}], "chart_points": "42.0,135.0 80.2,135.0 118.3,133.2 156.5,133.2 194.7,136.8 232.8,135.0 271.0,135.0 309.2,142.3 347.3,138.6 385.5,111.3 423.7,111.3 461.8,116.8 500.0,116.8 538.2,122.3 576.3,122.3 614.5,120.4 652.7,124.1 690.8,125.9 729.0,124.1 767.2,120.4 805.3,125.9 843.5,127.7 881.7,131.4 919.8,131.4 958.0,131.4", "changes": [{"tone": "neutral", "delta": 2, "label": "04 Sep 13:22", "score": 52, "height": 4, "articles": 15, "confidence": 19, "short_label": "04 Sep", "collected_at": "2026-09-04T13:22:23.652045+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "03 Sep 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 19, "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "02 Sep 23:59", "score": 52, "height": 4, "articles": 14, "confidence": 20, "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": -3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-2"}, {"tone": "neutral", "delta": 4, "label": "28 Aug 23:59", "score": 54, "height": 8, "articles": 17, "confidence": 26, "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -9, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 5, "label": "25 Aug 23:59", "score": 55, "height": 10, "articles": 26, "confidence": 25, "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -7, "score_change_display": "-3"}, {"tone": "positive", "delta": 8, "label": "21 Aug 23:59", "score": 58, "height": 16, "articles": 25, "confidence": 32, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "+2"}, {"tone": "neutral", "delta": 6, "label": "14 Aug 23:59", "score": 56, "height": 12, "articles": 26, "confidence": 30, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+1"}, {"tone": "neutral", "delta": 5, "label": "13 Aug 23:59", "score": 55, "height": 10, "articles": 25, "confidence": 25, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}